UnknownPhase 4

Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy

China96 participantsStarted 2022-07-01

Plain-language summary

Diabetic retinopathy has been found progress in 20-70% diabetic patient after cataract phacoemulsification surgery. Intravitreal injection of anti-VEGF Ranibizumab is an important treatment for diabetic retinopathy including non-proliferative diabetic retinopathy (NPDR). However, there is no research about phacoemulsification surgery combine Intravitreal injection of Ranibizumab on diabetic retinopathy. The research focus on the effect of phacoemulsification surgery combine intravitreal injection of Ranibizumab on mild non-proliferative diabetic retinopathy and explore the reasons for differences in treatment outcomes.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Signed and dated informed consent * Commitment to follow the research procedures and cooperate with the implementation of the whole process of research * No specific gender, 18+ years old * Diagnosed in line with NPDR, * Phacoemulsification combined with anti-VEGF therapy is planned * No obvious surgical contraindications Exclusion Criteria: * Use of other investigational drug treatments or take part in other types of clinical studies * Allergy to anti-VEGF drugs * Patients with other macular and optic disc diseases * Patients with meaningful diabetic macular edema * Patient with surgical complications

What they're measuring

capillary non-perfusion zone of non-proliferative diabetic retinopathy

Timeframe: 1 year

Trial details

NCT IDNCT05386160

SponsorRuijin Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-03-01

Contact for this trial

Zijian Yang, Dr.

+862167888999 dyangzj@163.com